KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics (PVLA) Capital Expenditures: 2014-2023

Historic Capital Expenditures for Palvella Therapeutics (PVLA) over the last 9 years, with Dec 2023 value amounting to -$13,000.

  • Palvella Therapeutics' Capital Expenditures fell 18.18% to -$13,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $171,000, marking a year-over-year decrease of 83.57%. This contributed to the annual value of $171,000 for FY2023, which is 83.57% down from last year.
  • Latest data reveals that Palvella Therapeutics reported Capital Expenditures of -$13,000 as of Q4 2023, which was down 118.84% from $69,000 recorded in Q3 2023.
  • Palvella Therapeutics' Capital Expenditures' 5-year high stood at $1.9 million during Q1 2020, with a 5-year trough of -$840,000 in Q3 2020.
  • Moreover, its 3-year median value for Capital Expenditures was $68,000 (2023), whereas its average is $180,083.
  • The largest annual percentage gain for Palvella Therapeutics' Capital Expenditures in the last 5 years was 1,492.56% (2020), contrasted with its biggest fall of 462.07% (2020).
  • Palvella Therapeutics' Capital Expenditures (Quarterly) stood at $1.2 million in 2019, then slumped by 50.85% to $578,000 in 2020, then tumbled by 40.83% to $342,000 in 2021, then slumped by 103.22% to -$11,000 in 2022, then decreased by 18.18% to -$13,000 in 2023.
  • Its Capital Expenditures stands at -$13,000 for Q4 2023, versus $69,000 for Q3 2023 and $67,000 for Q2 2023.